Skip to main content
Fig. 2 | Infectious Diseases of Poverty

Fig. 2

From: Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries

Fig. 2

Detection of TAM using AfriPOLA or DEEPGEN™HIV. a Relative mean fluorescence intensity (MFI) from each patient represented as percent of max value (MFI; calculated for ≥150 beads per well; +/− s.d.; N = 3 independent experiments). The maximal MFI for detection of any of the 9 mutations probed by AfriPOLA. Red dots indicate mutations not detected by Sanger sequencing. b Percent of patients within cohort (Table 1) with drug resistance to the indicated drugs based on genotype from AfriPOLA and Sanger sequencing. c Mutation frequency ≥1% for TAMs (M41 L, K65R, D67N, K70R, L74 V, Y115F, T215Y, K219Q, L210 W, and M184 V) as detected by DEEPGEN™HIV in each patient (Table 1). Previous studies have established DEEPGEN™HIV error rate, reproducibility and sensitivity [37]. d Box plot comparing DEEPGEN™HIV mutation frequency for all TAMs to AfriPOLA concordant and discordant result

Back to article page